Inhibitor-Mediated Programming of Glycoforms
The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.
Projectdetails
Introduction
Site-directed mutagenesis revolutionised the study of proteins and enabled the development of protein-based therapeutics. Our long-term vision is to have equivalent impact through the precise manipulation of the glycans (carbohydrates) on cells and recombinant proteins that will enable the discovery and production of the next generation of therapies for cancer, neurodegeneration, and other disease families.
Importance of Glycans
The glycans that are present on most proteins and cells have a substantial impact on their biological functions. However, the untemplated nature of their synthesis leads to inherent heterogeneity in both their structure and activity. This heterogeneity is very difficult to control, making it impossible to generate defined glycan ensembles with optimal activity using current technology.
New Approach
Here we present a radically new approach to the controlled manipulation of glycans that will be the functional equivalent of site-directed mutagenesis for manipulating proteins.
Methodology
We will use the delivery of computationally defined mixtures of enzyme-specific inhibitors to the site of glycan biosynthesis in the cell to tune the activity of glycosyltransferases. Our approach, termed Inhibitor-Mediated Programming of Glycoforms (IMProGlyco), will provide an effective strategy to manipulate the glycosylation machinery and thereby generate proteins with defined ensembles of glycans.
Applications
This technology will enable the production of precision glycan-engineered therapeutic proteins and vaccines. Moreover, shaping cellular glycan profiles will aid discovery science to uncover glycan functions and improve therapeutic cells, such as those used in Chimeric Antigen Receptors cell Therapy (CAR-T).
Future Prospects
Our technology will be adaptable and expandable into other cell types and organisms, allowing glycan shaping in all areas of eukaryotic cell biology to enable new biotechnological applications and fundamental studies of biology.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.998.878 |
Totale projectbegroting | € 2.998.878 |
Tijdlijn
Startdatum | 1-2-2025 |
Einddatum | 31-1-2028 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSITY OF LEEDSpenvoerder
- UNIVERSITY OF YORK
- UNIVERSITAET FUER BODENKULTUR WIEN
- OSLOMET - STORBYUNIVERSITETET
- OSLO UNIVERSITETSSYKEHUS HF
- GLYCOSELECT LTD
- CENTRE FOR PROCESS INNOVATION LIMITED LBG
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseasesThe project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications. | EIC Pathfinder | € 3.920.718 | 2024 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseases
The project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolutionGlyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment. | ERC Starting... | € 1.500.000 | 2023 | Details |
Engineering CAR-T cells to overcome glycosylation-driven tumour resistanceThe project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers. | ERC Starting... | € 1.500.000 | 2023 | Details |
Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infectionGLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment. | ERC Consolid... | € 1.994.024 | 2024 | Details |
A general approach for the design of covalent protein proximity inducersThis project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications. | ERC Consolid... | € 1.998.744 | 2024 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution
Glyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment.
Engineering CAR-T cells to overcome glycosylation-driven tumour resistance
The project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers.
Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infection
GLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment.
A general approach for the design of covalent protein proximity inducers
This project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications.